<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360696</url>
  </required_header>
  <id_info>
    <org_study_id>13100348</org_study_id>
    <nct_id>NCT02360696</nct_id>
  </id_info>
  <brief_title>Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children</brief_title>
  <official_title>Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Duodenal eosinophilia has been associated with dyspepsia in adults and the investigators have
      previously described the finding of duodenal mucosal eosinophilia in 71-79% of children
      undergoing diagnostic endoscopy. Previous studies in children have shown positive response to
      montelukast with approximately 50% finding complete relief and 20-30 percent showing no
      response.

      There are a number of factors that have the potential to contribute to the observed
      variability in response to montelukast. These include variability in:

        1. systemic drug exposure (drug absorption, biotransformation and/or elimination)

        2. regulation of leukotriene biosynthesis

        3. cysteinyl leukotriene receptors and downstream mediators

        4. patient disease phenotype (e.g. Functional Gastrointestinal Disorder (FGID) disease
           classification, psychologic profile)

      In this study, the investigators propose to utilize biopsy specimens stratified by drug
      response to identify candidate gene expression modules that will be validated in a
      prospective study design. The overall goal of this program is to develop a signature of
      montelukast response that can be applied not only to eosinophilic gastroenteritis, but more
      generally to other diseases, such as asthma, where the drug is widely used with variable
      success.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of a signature of montelukast response using gene expression patterns in biopsy samples from clinical responders and non-responders to montelukast.</measure>
    <time_frame>Approximately 7-8 weeks</time_frame>
    <description>Identification of patients who will benefit from montelukast therapy , allowing more efficient, and possibly more effective, care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization a signature of montelukast response using comparison gene expression patterns in biopsy samples obtained before and after montelukast therapy in children with a positive clinical response to the drug.</measure>
    <time_frame>7-8 weeks.</time_frame>
    <description>Identification and development of a signature of montelukast response applied to eosinophilic gastroenteritis, and more generally to other diseases, such as asthma, where the drug is widely used with variable success.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Eosinophilia</condition>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Peds/Adol Pts w/ FD - CMH GI APT clinic</arm_group_label>
    <description>Phase 1. Standard-of-Care Endoscopy to establish baseline data and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis. If participant biopsies meet criteria (&gt; or = 20/hpf) and no nodularity or tumors, s/he will be eligible to move to second phase.
Phase 2. Standard of care treatment of 3 mg/kg ranitidine bid and 20 mg. montelukast each AM for three weeks. Based on response to global assessment score, participants will be placed in non-responder or responder group. Participants from the responder group will move to final phase of the study.
Phase 3: Research endoscopy to measure response to montelukast therapy. Biopsies taken for cell density counts and immunohistochemistry studies. Additional biopsies taken for DNA and microarray analysis.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples retained, with potential for extraction of DNA from at least one of the types of
      samples retained.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 50 subjects (allowance of 20 additional subjects for screen fails and those who will
        not complete Phase 3 of the study) will be recruited from a cohort of patients referred to
        the Abdominal Pain Clinic at Children's Mercy Hospitals and Clinics and enrolled prior to
        routine initial endoscopy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 8 - 17 years, inclusive

          -  Abdominal pain of at least 8 weeks duration and fulfilling symptom- based criteria for
             functional dyspepsia

          -  Scheduled for endoscopy following failure to respond to acid-reduction therapy

          -  Evidence of written parental permission (consent) and subject assent

        Exclusion Criteria:

          -  Previous treatment with montelukast

          -  Treatment with corticosteroids or oral cromolyn sodium in the four weeks prior to
             enrollment

          -  Prior history or clinical signs/symptoms of chronic disease requiring regular medical
             care (e.g., diabetes mellitus, juvenile idiopathic arthritis, cystic fibrosis or
             cancer)

          -  Exposure within the past two weeks to drugs or natural products that induce CYP2C8/9
             or CYP3A4, including amprenavir, carbamazepine, lopinavir/ritonavir, nafcillin,
             nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifampin, St. John's Wort, or
             that inhibit CYP2C8/9 or CYP3A4, such as ciprofloxacin, clarithromycin, erythromycin,
             fluconazole, fluvoxamine, grapefruit juice, paroxetine, sertraline, sulfamethoxazole,
             trimethoprim

          -  A Body Mass Index of 30 or greater

          -  Non-English speaking

          -  Those patients who will turn 18 during the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A. Friesen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy, Division of Gastroenterlogy, Hepatology, and Nutrition</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Leeder, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy, Division of Clinical Pharmacology and Medical Toxicology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy E. Lathrom, CCRC</last_name>
    <phone>816.855.1860</phone>
    <email>nelathrom@cmh.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Craig A. Friesen, MD</last_name>
    <phone>816.3016</phone>
    <email>cfriesen@cmh.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Mercy</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy E. Lathrom, CCRC</last_name>
      <phone>816-855-1860</phone>
      <email>nelathrom@cmh.edu</email>
    </contact>
    <contact_backup>
      <last_name>Craig A. Friesen, MD</last_name>
      <phone>816.234.3016</phone>
      <email>cfriesen@cmh.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jennifer V. Schurman, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Leeder, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig A. Friesen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shui Q. Ye, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nancy E. Lathrom, CCRC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevor J. Cole, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Talley NJ, Walker MM, Aro P, Ronkainen J, Storskrubb T, Hindley LA, Harmsen WS, Zinsmeister AR, Agréus L. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct;5(10):1175-83. Epub 2007 Aug 7.</citation>
    <PMID>17686660</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Neilan NA, Schurman JV, Taylor DL, Kearns GL, Abdel-Rahman SM. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009 May 11;9:32. doi: 10.1186/1471-230X-9-32.</citation>
    <PMID>19432972</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Sandridge L, Andre L, Roberts CC, Abdel-Rahman SM. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006 Mar;45(2):143-7.</citation>
    <PMID>16528434</PMID>
  </reference>
  <reference>
    <citation>Erjefält JS, Greiff L, Andersson M, Adelroth E, Jeffery PK, Persson CG. Degranulation patterns of eosinophil granulocytes as determinants of eosinophil driven disease. Thorax. 2001 May;56(5):341-4.</citation>
    <PMID>11312400</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Andre L, Garola R, Hodge C, Roberts C. Activated duodenal mucosal eosinophils in children with dyspepsia: a pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):329-33.</citation>
    <PMID>12352522</PMID>
  </reference>
  <reference>
    <citation>Hall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori-negative functional dyspepsia. Clin Gastroenterol Hepatol. 2003 Sep;1(5):363-9.</citation>
    <PMID>15017654</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Lin Z, Singh M, Singh V, Schurman JV, Burchell N, Cocjin JT, McCallum RW. Antral inflammatory cells, gastric emptying, and electrogastrography in pediatric functional dyspepsia. Dig Dis Sci. 2008 Oct;53(10):2634-40. doi: 10.1007/s10620-008-0207-0. Epub 2008 Mar 5.</citation>
    <PMID>18320315</PMID>
  </reference>
  <reference>
    <citation>Muijsers RB, Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs. 2002;4(2):123-39. Review.</citation>
    <PMID>11888359</PMID>
  </reference>
  <reference>
    <citation>Neustrom MR, Friesen C. Treatment of eosinophilic gastroenteritis with montelukast. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):506.</citation>
    <PMID>10452782</PMID>
  </reference>
  <reference>
    <citation>Schwartz DA, Pardi DS, Murray JA. Use of montelukast as steroid-sparing agent for recurrent eosinophilic gastroenteritis. Dig Dis Sci. 2001 Aug;46(8):1787-90.</citation>
    <PMID>11508684</PMID>
  </reference>
  <reference>
    <citation>Vanderhoof JA, Young RJ, Hanner TL, Kettlehut B. Montelukast: use in pediatric patients with eosinophilic gastrointestinal disease. J Pediatr Gastroenterol Nutr. 2003 Feb;36(2):293-4.</citation>
    <PMID>12548071</PMID>
  </reference>
  <reference>
    <citation>Friesen CA, Kearns GL, Andre L, Neustrom M, Roberts CC, Abdel-Rahman SM. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):343-51.</citation>
    <PMID>15076638</PMID>
  </reference>
  <reference>
    <citation>Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos. 1997 Sep;25(9):1022-31.</citation>
    <PMID>9311616</PMID>
  </reference>
  <reference>
    <citation>Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, Backman JT. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther. 2010 Aug;88(2):223-30. doi: 10.1038/clpt.2010.73. Epub 2010 Jun 30.</citation>
    <PMID>20592724</PMID>
  </reference>
  <reference>
    <citation>Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab Dispos. 2011 May;39(5):904-11. doi: 10.1124/dmd.110.037689. Epub 2011 Feb 2.</citation>
    <PMID>21289076</PMID>
  </reference>
  <reference>
    <citation>Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510. doi: 10.2217/pgs.09.82.</citation>
    <PMID>19761371</PMID>
  </reference>
  <reference>
    <citation>Rodríguez-Antona C, Niemi M, Backman JT, Kajosaari LI, Neuvonen PJ, Robledo M, Ingelman-Sundberg M. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J. 2008 Aug;8(4):268-77. Epub 2007 Oct 9.</citation>
    <PMID>17923851</PMID>
  </reference>
  <reference>
    <citation>Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008 Nov;392(6):1093-108. doi: 10.1007/s00216-008-2291-6. Epub 2008 Aug 10. Review.</citation>
    <PMID>18695978</PMID>
  </reference>
  <reference>
    <citation>Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c.</citation>
    <PMID>19151602</PMID>
  </reference>
  <reference>
    <citation>Mougey EB, Lang JE, Wen X, Lima JJ. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011 May;51(5):751-60. doi: 10.1177/0091270010374472. Epub 2010 Oct 25.</citation>
    <PMID>20974993</PMID>
  </reference>
  <reference>
    <citation>Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157-67. Review.</citation>
    <PMID>13679531</PMID>
  </reference>
  <reference>
    <citation>Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P, Blake K, van Nispen CH, Noonan G, Freeman A, Haesen R, Michiels N, Rogers JD, Amin RD, Zhao J, Xu X, Seidenberg BC, Gertz BJ, Spielberg S. Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol. 1999 Aug;39(8):786-93.</citation>
    <PMID>10434229</PMID>
  </reference>
  <reference>
    <citation>Duroudier NP, Tulah AS, Sayers I. Leukotriene pathway genetics and pharmacogenetics in allergy. Allergy. 2009 Jun;64(6):823-39. doi: 10.1111/j.1398-9995.2009.02015.x. Epub 2009 Mar 26. Review.</citation>
    <PMID>19416143</PMID>
  </reference>
  <reference>
    <citation>Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006 Feb 15;173(4):379-85. Epub 2005 Nov 17.</citation>
    <PMID>16293801</PMID>
  </reference>
  <reference>
    <citation>Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010;85(6):336-49. doi: 10.1159/000312669. Epub 2010 Jun 2. Review.</citation>
    <PMID>20516735</PMID>
  </reference>
  <reference>
    <citation>Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther. 2007;11(2):97-104. Review.</citation>
    <PMID>17397245</PMID>
  </reference>
  <reference>
    <citation>Sampson AP, Pizzichini E, Bisgaard H. Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S49-59; discussion S59-61. Review.</citation>
    <PMID>12532086</PMID>
  </reference>
  <reference>
    <citation>Bizzintino JA, Khoo SK, Zhang G, Martin AC, Rueter K, Geelhoed GC, Goldblatt J, Laing IA, Le Souëf PN, Hayden CM. Leukotriene pathway polymorphisms are associated with altered cysteinyl leukotriene production in children with acute asthma. Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):9-15. doi: 10.1016/j.plefa.2009.05.022. Epub 2009 Jun 12.</citation>
    <PMID>19524426</PMID>
  </reference>
  <reference>
    <citation>Bischoff SC, Lorentz A, Schwengberg S, Weier G, Raab R, Manns MP. Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue. Gut. 1999 May;44(5):643-52.</citation>
    <PMID>10205200</PMID>
  </reference>
  <reference>
    <citation>Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy. 2006 Jun;36(6):689-703. Review.</citation>
    <PMID>16776669</PMID>
  </reference>
  <reference>
    <citation>Aguillón JC, Cruzat A, Aravena O, Salazar L, Llanos C, Cuchacovich M. Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution? Immunobiology. 2006;211(1-2):75-84. Epub 2005 Dec 27. Review.</citation>
    <PMID>16446172</PMID>
  </reference>
  <reference>
    <citation>de Vries N, Tak PP. The response to anti-TNF-alpha treatment: gene regulation at the bedside. Rheumatology (Oxford). 2005 Jun;44(6):705-7. Epub 2005 Apr 26.</citation>
    <PMID>15855186</PMID>
  </reference>
  <reference>
    <citation>Maeba S, Ichiyama T, Ueno Y, Makata H, Matsubara T, Furukawa S. Effect of montelukast on nuclear factor kappaB activation and proinflammatory molecules. Ann Allergy Asthma Immunol. 2005 Jun;94(6):670-4.</citation>
    <PMID>15984600</PMID>
  </reference>
  <reference>
    <citation>Kim SH, Yang EM, Kim SH, Park HS. Regulation of monocyte chemoattractant protein 1 by cysteinyl leukotriene D4 in human lung epithelial A549 cells. Ann Allergy Asthma Immunol. 2009 Oct;103(4):358-9. doi: 10.1016/S1081-1206(10)60540-6.</citation>
    <PMID>19852204</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Danda CE, Friesen CA, Hyman PE, Simon SD, Cocjin JT. Variations in psychological profile among children with recurrent abdominal pain. J Clin Psychol Med Settings. 2008 Sep;15(3):241-51. doi: 10.1007/s10880-008-9120-0. Epub 2008 Jul 25.</citation>
    <PMID>19104969</PMID>
  </reference>
  <reference>
    <citation>Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology. 2006 Apr;130(5):1466-79. Review. Erratum in: Gastroenterology. 2006 Jul;131(1):336.</citation>
    <PMID>16678560</PMID>
  </reference>
  <reference>
    <citation>Schurman JV, Singh M, Singh V, Neilan N, Friesen CA. Symptoms and subtypes in pediatric functional dyspepsia: relation to mucosal inflammation and psychological functioning. J Pediatr Gastroenterol Nutr. 2010 Sep;51(3):298-303. doi: 10.1097/MPG.0b013e3181d1363c.</citation>
    <PMID>20479684</PMID>
  </reference>
  <reference>
    <citation>Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21. Epub 2001 Apr 17. Erratum in: Proc Natl Acad Sci U S A 2001 Aug 28;98(18):10515.</citation>
    <PMID>11309499</PMID>
  </reference>
  <reference>
    <citation>Efron B, Tibshirani R, Storey JD, Tusher V. Empirical Bayes analysis of a microarray experiment. J Am Stat Assoc 2001;96:1151-1160.</citation>
  </reference>
  <reference>
    <citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995;57:289-300.</citation>
  </reference>
  <reference>
    <citation>Kazani S, Wechsler ME, Israel E. The role of pharmacogenomics in improving the management of asthma. J Allergy Clin Immunol. 2010 Feb;125(2):295-302; quiz 303-4. doi: 10.1016/j.jaci.2009.12.014. Review.</citation>
    <PMID>20159237</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <last_update_submitted>February 5, 2015</last_update_submitted>
  <last_update_submitted_qc>February 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Mercy Hospital Kansas City</investigator_affiliation>
    <investigator_full_name>Craig A. Friesen, MD</investigator_full_name>
    <investigator_title>Section Chief/Division of Gastroenteroly, Hepatology, and Nutrition</investigator_title>
  </responsible_party>
  <keyword>Duodenal Eosinophilia</keyword>
  <keyword>Functional Dyspepsia</keyword>
  <keyword>Mucosal Eosinophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Eosinophilia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

